NIH RFA · OD · R01
RFA-OD-27-004: INCLUDE Project: Transformative Research Awards for Down syndrome (R01 Clinical Trial Not Allowed)
Reviewed by Dr. Meng ZhaoLast reviewed October 16, 2026Data refreshed October 16, 2026Editorial standards
The NIH INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE (INCLUDE) Project seeks to improve health and quality-of-life for individuals with Down syndrome. The purpose of this Notice of Funding Opportunity (NOFO) is to solicit Transformative Research Award applications to support individual scientists or groups of scientists proposing groundbreaking, exceptionally innovative, original, and/or unconventional research that has the potential to create new scientific paradigms, establish entirely new and improved clinical approaches, or develop transformative technologies related to Down syndrome. Applications are welcome in all topics relevant to Down…
- NOFO number
- RFA-OD-27-004
- Type
- RFA
- Activity code
- R01
- Primary institute
- OD · NIH Office of the Director
- Clinical trials
- Not Allowed
- Posted
- May 12, 2026
- Opens
- Sep 15, 2026
- Expires
- Jun 16, 2028
RFA-OD-27-004 due dates
2 application due dates remain before the NOFO expires. Dates marked * are NIH standard due dates. Check the related notices below for changes NIH made after posting.
| New | Renewal / Resubmission / Revision (as allowed) | AIDS - New/Renewal/Resubmission/Revision, as allowed | Scientific Merit Review | Advisory Council Review | Earliest Start Date |
|---|---|---|---|---|---|
| October 15, 2026 | October 15, 2026 | Not Applicable | March 2027 | May 2027 | July 2027 |
| June 15, 2027 | June 15, 2027 | Not Applicable | November 2027 | January 2028 | April 2028 |
| June 15, 2028 | June 15, 2028 | Not Applicable | November 2028 | January 2029 | April 2029 |
What its predecessor RFA-OD-22-009 funded
RFA-OD-27-004 reissues RFA-OD-22-009. Until awards appear under the new number, its funding history is the best guide to who wins under this program: 25 projects and $49.5M in FY2022–FY2026.
Projects funded
25
Distinct projects, FY2022–FY2026
New awards
22
Type 1 (new project) award records
NIH funding
$49.5M
Award dollars under RFA-OD-22-009, FY2022–FY2026
Funding by fiscal year
| Fiscal year | Award records | New awards | Funding |
|---|---|---|---|
| FY2022 | 0 | 0 | $0 |
| FY2023 | 10 | 10 | $21.5M |
| FY2024 | 7 | 7 | $4.6M |
| FY2025 | 12 | 4 | $9.3M |
| FY2026 | 19 | 1 | $14.1M |
Institutions with the most funding
- University of Colorado Denver$9.8M · 5 projects
- University of Chicago$6.6M · 1 project
- Texas A&M Agrilife Research$4.8M · 3 projects
- Icahn School of Medicine at Mount Sinai$3.8M · 2 projects
- University of California-Irvine$3.2M · 1 project
- Virginia Commonwealth University$3.0M · 1 project
- Broad Institute, Inc.$2.7M · 1 project
- Pennsylvania State University, the$2.7M · 1 project
Funding institutes
- NICHD$18.8M · 12
- NIA$11.6M · 12
- NINDS$7.5M · 7
- NIDCD$5.6M · 5
- NCI$3.8M · 9
- NIDCR$2.3M · 2
- NEI$1 · 1
Activity codes funded
- R0143 records
- RF15 records
Most recent new awards
- HMNG1 exacerbates neuropathology in Down Syndrome-associated Alzheimer's through its epigenetic and alarmin activity. (opens NIH RePORTER)
Boston University Medical Campus · 1R01AG093434-01 · NIA · Notice Aug 20, 2026
$763KR01
- Modifiers of Down Syndrome Co-occurring Phenotypes (opens NIH RePORTER)
Indiana University Indianapolis · 1R01HD118475-01 · NICHD · Notice Jul 30, 2025
$1.3MR01
- Transposable Element Mobilization and Disrupted Translational Machinery in Down Syndrome (opens NIH RePORTER)
Boston Children's Hospital · 1RF1NS142871-01 · NINDS · Notice Jul 30, 2025
$1.3MRF1
- A humanized monoclonal FSH antibody for Alzheimer's Disease and co-occurring health conditions in Down Syndrome (opens NIH RePORTER)
Icahn School of Medicine at Mount Sinai · 1R01AG093773-01 · NIA · Notice Jun 19, 2025
$1.3MR01
- Allelic Expression Imbalance in Trisomy 21 (opens NIH RePORTER)
Oregon Health & Science University · 1RF1NS142814-01 · NINDS · Notice Jun 13, 2025
$780KRF1
- The role of immune deregulation and NGF dysmetabolism in the development of Alzheimer disease in individuals with Down syndrome (opens NIH RePORTER)
University of California-Irvine · 1R01AG087280-01 · NIA · Notice Aug 6, 2024
$1.1MR01
FY2026 closed on September 30, 2026, but NIH keeps posting that year's awards to RePORTER for several weeks. FY2026 figures reflect records available on October 16, 2026 and may rise slightly at the next refresh.
Participating institutes
15 NIH institutes and offices take applications under RFA-OD-27-004. Contact the program officer at the institute that fits your research before applying.
- OD · NIH Office of the Director
- NEI · National Eye Institute
- NHLBI · National Heart, Lung, and Blood Institute
- NIA · National Institute on Aging
- NIAID · National Institute of Allergy and Infectious Diseases
- NIAMS · National Institute of Arthritis and Musculoskeletal and Skin Diseases
- NICHD · Eunice Kennedy Shriver National Institute of Child Health and Human Development
- NIDCD · National Institute on Deafness and Other Communication Disorders
- NIDCR · National Institute of Dental and Craniofacial Research
- NIDDK · National Institute of Diabetes and Digestive and Kidney Diseases
- NIMH · National Institute of Mental Health
- NLM · National Library of Medicine
- NCATS · National Center for Advancing Translational Sciences
- ORIP
- NCI · National Cancer Institute
Related notices
NIH lists no related notices for RFA-OD-27-004 yet.
Award terms
- Application types allowed
- New Renewal Resubmission Revision The OER Glossary and the How to Apply Application Guide provide details on these application types. Only those application types listed here are allowed for this NOFO.
- Award budget
- Application budgets are limited to a maximum of 500,000 direct costs per year of the award.
- Project period
- The maximum project period is five years. NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made from this NOFO.
- Funds available and number of awards
- NIH intends to commit an estimated 3,000,000 to fund up to 4 awards per year in FY2027, FY2028, and FY2029.The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Future year amounts will depend on annual appropriations.
Summarized from the NOFO text; the full NOFO governs eligibility, budget, and review.
Related NOFOs
- Reissue of RFA-OD-22-009.
Other open NOFOs for R01
- PAR-25-322Stephen I. Katz Early Stage Investigator Research Project Grant (R01 Clinical Trial Not Allowed)OD · next due Jan 26, 2027
- PAR-25-077CCRP Initiative: NIH Countermeasures Against Chemical Threats (CounterACT) Basic Research on Chemical Threats that Affect the Nervous System (R01 Clinical Trial Not Allowed)NINDS · next due Oct 16, 2026
- PAR-25-371Ethical, Legal and Social Implications (ELSI) Research (R01 Clinical Trial Optional)NHGRI · next due Oct 20, 2026
- PAR-25-271NCCIH Natural Product Mid Phase Clinical Trial (R01 Clinical Trial Required)NCCIH · next due Oct 20, 2026
- PAR-25-267NCCIH Multi-Site Feasibility Clinical Trials of Mind and Body Interventions (R01 Clinical Trial Required)NCCIH · next due Oct 20, 2026
- PAR-25-268Investigator Initiated Clinical Trials of Complementary and Integrative Interventions Delivered Remotely or via mHealth (R01 Clinical Trial Required)NCCIH · next due Oct 20, 2026
About this page
GotGrant gathers the NOFO, its participation and change notices, and its NOSIs from the NIH Guide for Grants and Contracts, and counts funded projects from NIH RePORTER by the opportunity number each award was made under. Data refreshed October 16, 2026; the NIH Guide is the authoritative source. See our data methodology.